High farnesoid X receptor expression predicts favorable clinical outcomes in PD-L1(low/negative) non-small cell lung cancer patients receiving anti-PD-1-based chemo-immunotherapy

Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)-directed immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). However, predictive biomarkers are still lacking, particularly in identifying PD-L1(low/negative) patients who will benefit from im...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lina, Xu, Xiaolong, Shang, Bin, Sun, Jian, Liang, Bin, Wang, Xingguang, You, Wenjie, Jiang, Shujuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923651/
https://www.ncbi.nlm.nih.gov/pubmed/35211760
http://dx.doi.org/10.3892/ijo.2022.5330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923651/
https://www.ncbi.nlm.nih.gov/pubmed/35211760
http://dx.doi.org/10.3892/ijo.2022.5330

Ejemplares similares